For mass medication of broiler, layer, and turkey flocks through the drinking-water route, Houyanjing Powder Veterinary Grade API is first converted into a water-dispersible oral powder rather than being directly dissolved, because the extract contains poorly wettable lignified plant fragments that float and create uneven dosing in nipple drinker systems. The formulation addition ratio is typically 0.5 g/L to 2.0 g/L of final drinking water, with the upper limit reserved for acute respiratory outbreak protocols and the lower limit applied in prolonged prophylactic cycles; the ratio is expressed as extract weight per liter and must be re-calculated per batch using the marker compound assay for total flavonoids, because raw botanical extract lots vary in density by ±8%. Published data for this specific configuration is limited, so the exact addition ratio is validated by the downstream manufacturer’s stability protocol rather than taken from compendial fixed values. In industry compliance terms, this application falls under non-sterile oral veterinary medicinal product requirements: EU Regulation 2019/6, VICH GL1 for analytical method validation, VICH GL2 for stability protocols, Ph. Eur. monograph 5.1.4 for microbiological quality of non-sterile products, and EU GMP Annex 2 for active substance handling. Downstream production equipment is typically a 500 kg ribbon blender or high-shear ploughshare mixer operated at 25 rpm for 8 min with a preblend stage: the extract is first combined with dextrose monohydrate at a 1:10 ratio, then with anhydrous citric acid at 0.5% to 1.0% to buffer alkaline water hardness and reduce oxidation of phenolic marker compounds. The preblend is sieved through a 500 µm conical mill and packed into foil-lined heat-sealed sachets under ≤30% relative humidity. Finished dosage forms include 100 g, 500 g, and 1 kg water-soluble powder sachets, as well as dosing-pump liquid concentrates reconstituted farm-side; the powder form is specified for export because its water activity is maintained below 0.60, which limits microbial proliferation during tropical shipping without requiring cold-chain logistics.

What sterility assurance level applies to Houyanjing injection manufacturing?

Terminally sterilised injectable solutions containing Houyanjing Powder require a sterility assurance level of 10⁻⁶ per Ph. Eur. 5.1.1 and EU GMP Annex 1; if the powder is aseptically filtered without terminal heat, the process must be validated with media fills under ISO 14644-1:2015 Class 5 conditions. The formulation addition ratio for parenteral solutions ranges from 2.0% w/v to 10.0% w/v of extract powder, adjusted to deliver 5 mg/mL to 20 mg/mL of marker flavonoids in Water for Injection, with pH adjusted to 6.0–7.5 using 0.1 M sodium hydroxide or hydrochloric acid. Compliance standards for this route include Ph. Eur. 2.9.9 for sub-visible particulate contamination, USP <788> for particulate matter in injections, VICH GL10 for impurity thresholds in new veterinary drug substances, and 21 CFR 211.113 for sterilisation process validation. Downstream production begins with dissolution at 35–40°C in a jacketed stainless steel vessel with bottom magnetic agitation; the solution is chilled to 20°C, clarified through 0.45 µm polyethersulfone capsules, then sterilised through 0.22 µm PVDF membrane filters in series. Filling into Type I borosilicate vials is conducted under unidirectional airflow with an area velocity of 0.45 m/s ± 20%, followed by terminal autoclaving at 121°C for 15 min if the marker compound stability data permit; thermolabile lots are aseptically filtered and sealed without terminal heat, but then the maximum bioburden before filtration must be ≤10 CFU/100 mL and the filter integrity bubble point tested before and after filling. Endotoxin limits are set at ≤0.5 EU/mL for mammalian parenteral products. The terminal presentation consists of 10 mL, 20 mL, 50 mL, and 100 mL multi-dose rubber-stoppered vials for intramuscular or subcutaneous administration in swine, cattle, and companion animals.

Feed premix carrier selection and segregation thresholds

The highest segregation risk is not at the final feed mill but during the first dilution of Houyanjing Powder into a carrier premix, because the extract particle density of 0.45–0.60 g/cm³ is substantially lower than corn meal particles, causing upward migration during pneumatic conveying. The formulation addition ratio for medicated premix ranges from 0.1 kg to 1.0 kg of API per 1000 kg final complete feed, but direct addition at this concentration is prohibited; a two-step geometric dilution is required, beginning at 1:10 with calcium carbonate of controlled particle size 180–250 µm, followed by a second 1:10 dilution onto wheat bran or rice husk carrier. Compliance obligations include 21 CFR 225 for medicated feed manufacturing, 21 CFR 558 registration for new animal drugs in feed, EU Regulation 1831/2003 for feed additive categories, ISO 22000:2018 food safety management, and GMP+ B2 for feed safety assurance. Production equipment is a horizontal ribbon mixer with a working volume of 1000 kg and a tip speed of 3–5 m/s; the mixer is filled to 60–70% of gross volume, and mixing time is validated by tracer studies to achieve a coefficient of variation ≤5% across 10 sampling points. Carrier moisture must be below 12% before addition, and 0.25% food-grade mineral oil is sprayed into the finished premix to reduce dust and electrostatic charge. This route yields 5 kg, 20 kg, and 25 kg multilayer paper bags with inner polyethylene liners, intended for incorporation into complete feed at the mill or as top-dress powders for swine and poultry farms; the premix form is selected where water medication is not feasible due to automatic nipple drinker clogging.

Compression of Houyanjing Powder into companion animal tablets confronts a measurable plastic deformation limit because the extract contains residual polysaccharides that reduce powder flowability and increase hygroscopicity above 60% relative humidity; therefore the manufacturing process is configured around low-moisture wet granulation rather than direct compression. The formulation addition ratio is 5% w/w to 20% w/w of extract per tablet core, with a common 150 mg extract loading in a 750 mg tablet for dogs and a 50 mg extract loading in a 250 mg tablet for cats, the remainder consisting of microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate. Compliance standards for this non-sterile oral tablet route include Ph. Eur. 2.9.8 resistance to crushing, Ph. Eur. 2.9.1 disintegration, USP <1217> tablet breaking force, USP <905> uniformity of dosage units, and VICH GL2 stability protocols for climatic zones III and IV. Downstream production is carried out in a high-shear granulator with impeller speed 300 rpm and chopper speed 1500 rpm, using purified water as binder at 10–15% w/w; wet granules are dried in a fluid-bed dryer at 55°C until loss on drying is 2.0–4.0%, then milled through a 1.0 mm screen. Compression is performed on a rotary tablet press with precompression force 5 kN and main compression force 8–18 kN, targeting tablet hardness of 30–70 N, friability ≤1.0%, and disintegration ≤15 min in 0.1 M hydrochloric acid at 37°C. Finished dosage forms include flat-faced scored tablets, chewable tablets with liver-based flavor coating, and film-coated tablets; the scored tablet format supports dose adjustment by body weight in companion animal veterinary practice.

When direct-fill capsules replace granulated tablets for feline dosing

Direct-fill capsule manufacturing for feline dosing avoids aqueous granulation but introduces a different constraint: the angle of repose of the milled extract–lubricant blend must remain below 35° to maintain die filling uniformity, and the API must be milled to D₉₀ ≤ 100 µm to prevent demixing during the capsule filling cycle. The formulation addition ratio in capsules ranges from 10% w/w to 30% w/w of total fill weight, for example 125 mg extract in a size 1 capsule with total fill weight of 400 mg, using lactose monohydrate as the bulking diluent and magnesium stearate at 0.5% w/w as lubricant. Industry compliance standards applied to this dosage form include Ph. Eur. 2.9.5 uniformity of mass of single-dose preparations, Ph. Eur. 2.9.1 disintegration of capsules, USP <905> uniformity of dosage units, VICH GL1 analytical method validation, and 21 CFR 211.113 process validation for marketed veterinary products. Downstream processing uses a V-blender or bin blender at 25 rpm for 15 min, followed by an automatic capsule filling machine with dosator or tamping-pin stations operating at 30,000 capsules/hour; fill weight variability is controlled within ±3% and reject stations remove empty, split, and crushed capsules using capacitance and infrared sensors. Because the extract is hygroscopic, the filling room is maintained at 20–25°C and ≤40% relative humidity, and the capsules are packed in PVC/aluminium blisters with desiccant canisters immediately after metal detection. The manufactured capsule types include hard gelatin and hydroxypropyl methylcellulose capsules in 50 mg, 125 mg, and 250 mg extract strengths; the HPMC variant is specified for export to halal and vegetarian segments where porcine gelatin is unacceptable.

Extrusion-spheronization of Houyanjing Powder into equine oral granules is selected only when the target dose exceeds the practical limit of a size 0 capsule, typically above 500 mg per administration, because the granular dosage form permits incorporation of palatability masking agents and controlled-release coatings without excessively increasing dose mass. The formulation addition ratio is 1% w/w to 5% w/w of extract in the final granule mass, with a representative composition of 2% w/w API, 55% w/w microcrystalline cellulose, 35% w/w lactose monohydrate, 3% w/w povidone binder, and 5% w/w sodium starch glycolate as disintegrant. Compliance standards include Ph. Eur. 2.9.10 sieve test for particle size distribution, Ph. Eur. 2.9.17 flowability, USP <786> analytical sieving, VICH GL2 stability testing, and ISO 3310-1:2016 test sieve specifications. The downstream process begins with dry blending in a planetary mixer, followed by wet granulation with purified water to a moisture content of 20–25%; the wet mass is extruded through a dome or radial screen extruder with 0.8–1.0 mm apertures and spheronized at 800–1200 rpm for 3–5 min until roundness exceeds 0.85. The spheres are dried in a fluid-bed dryer at 40°C to a final loss on drying ≤3.0%, sieved between 0.25 mm and 1.25 mm, and coated with a pH-dependent enteric polymer if the dose must bypass gastric degradation. The resulting presentations comprise 10 g, 25 g, and 100 g single-dose sachets, multi-dose tubs with calibrated scoops, and granules premeasured for mixing into pelleted feed for equine respiratory conditions; the granular route is specified when weight-based dosing for foals and adult horses requires fractional dose adjustment.

Lyophilized cake collapse begins above the measured Tg' of the freeze-concentrated solution

Freeze-dried injection powder containing Houyanjing extract requires mapping of the glass transition temperature of the maximally freeze-concentrated solution before the lyophilization cycle is fixed, because primary drying above Tg' causes cake collapse and higher residual moisture. The formulation addition ratio for lyophilized injection powder is expressed on a dry solids basis: the extract comprises 20% w/w to 60% w/w of total dry solids, with mannitol or glycine as the crystallizing bulking excipient at 40% w/w to 80% w/w; the pre-lyophilization liquid fill volume is 5 mL to 10 mL per vial with total solids of 5% w/v to 15% w/v. Compliance standards for this route include Ph. Eur. 5.1.1 for sterile preparation, EU GMP Annex 1 for aseptic processing, USP <922> water activity for lyophilized solids, VICH GL10 for degradation product limits, and 21 CFR 211.113 for process validation. Downstream manufacture consists of sterile filtration of the bulk solution through 0.22 µm PVDF filters into depyrogenated vials, followed by lyophilization with a shelf ramping cycle from −40°C to +30°C over 48 h; primary drying is executed at a shelf temperature of −20°C and chamber pressure of 0.1 mbar for 24 h, while secondary drying is performed at +30°C and 0.05 mbar for 6 h to reduce residual moisture below 2.0%. The cake appearance index is inspected for collapse, meltback, and shrinkage; vials with cracked or lifted cakes are rejected by machine vision. Finished parenteral forms include single-use vials containing 100 mg, 250 mg, and 500 mg of lyophilized extract, paired with diluent ampoules for reconstitution to 5 mL or 10 mL injection volume; this form is used where the marker compounds are not thermostable enough for terminal steam sterilisation.